Working… Menu
Trial record 12 of 173 for:    pertuzumab

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02326974
Recruitment Status : Active, not recruiting
First Posted : December 30, 2014
Last Update Posted : January 15, 2019
Genentech, Inc.
Information provided by (Responsible Party):
Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : June 18, 2018
Estimated Study Completion Date : April 2022